Edesa Biotech
Yahoo Finance • 21 days ago
Top Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignment
(RTTNews) - Today's top gainers include Boundless Bio, which is combining with privately held Serapha; Monopar, on track for an NDA submission of ALXN1840 for Wilson disease; Jade Biosciences, advancing its autoimmune disease pipeline; and... Full story
Yahoo Finance • last month
Top Midday Stories: Lululemon Down After Fiscal Q1 Results; Amazon Engineers Criticize AI Spending; Hoffman to Exit Microsoft Board
All three major US stock indexes were down late Friday morning following a better-than-expected May PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story
Yahoo Finance • 2 months ago
MTVA Gains Weight, CODX Takes A Shot At Ebola, EDSA To Reveal New Data, BDTX On Watch
(RTTNews) - As hedge fund tycoon George Soros once said, "It's not whether you're right or wrong that's important, but how much money you make when you're right and how much you lose when you're wrong." The following biotech stocks were am... Full story
Yahoo Finance • 3 months ago
Edesa Biotech (EDSA) Reaffirms 2026 Clinical Study Timeline for Vitiligo Treatment
Edesa Biotech Inc. (NASDAQ:EDSA) is one of the 10 Unstoppable Stocks That Could Double Your Money. Edesa Biotech Inc. (NASDAQ:EDSA) is one of the unstoppable stocks that could double your money. On March 26, Edesa reaffirmed that enrollm... Full story
Yahoo Finance • 7 months ago
Edesa Biotech GAAP EPS of -$1.27 beats by $0.51
* Edesa Biotech press release [https://seekingalpha.com/pr/20338470-edesa-biotech-reports-fiscal-year-2025-results] (EDSA [https://seekingalpha.com/symbol/EDSA]): FY GAAP EPS of -$1.27 beats by $0.51. * At September 30, 2025, Edesa had... Full story
Yahoo Finance • 9 months ago
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study
Study met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with clinically meaningful improvement in survival and recovery Paridiprubart exhibited consist... Full story
Yahoo Finance • 11 months ago
Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
New York, USA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vitiligo Clinical Trial Pipeline Accelerates as 18+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight The vitiligo treatment landscape is evolving with a shift tow... Full story
Yahoo Finance • 11 months ago
Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results
TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results... Full story
- NVDA
Mentioned:
Yahoo Finance • 12 months ago
Edesa Biotech files $150M mixed securities shelf offering
* Edesa Biotech (NASDAQ:EDSA [https://seekingalpha.com/symbol/EDSA]) has filed to offer up to $150M in a mix of securities. * The offering may include common shares, preferred shares, warrants, debt securities, subscription rights, and... Full story
Yahoo Finance • last year
Edesa Biotech Announces Chief Financial Officer Transition
TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment... Full story
Yahoo Finance • last year
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results
TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results... Full story
Yahoo Finance • last year
Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to fund Edesa’s CXCL10 antibody program through the end of fiscal 2026 TORONTO, Feb. 13, 2025 (... Full story